Pharma Capital

CymaBay Therapeutics' shares shoot up on phase 2 data for liver drug

The results were from the ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC)
livercancer_596ccc2790147.jpg
Primary biliary cholangitis (PBC) is a life-threatening and life-limiting chronic cholestatic liver disease

Shares in CymaBay Therapeutics Inc (NASDAQ:CBAY) rose over 25% to $7.08 on Monday on positive phase 2 trial results.

The results were from the ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a life-threatening and life-limiting chronic cholestatic liver disease.

Seladelpar is in development for the treatment of liver diseases PBC and Nonalcoholic steatohepatitis (NASH).

After sharing preliminary results from this study, the FDA has agreed to allow continuation of seladelpar treatment beyond six months for the 5 mg and 10 mg doses, the group revealed.

"The data emerging from this study are impressive and support our hypothesis that lower doses of seladelpar than previously studied retain strong efficacy without raising a concern with transaminase elevations," said Professor Gideon Hirschfield, Centre for Liver Research at the University of Birmingham, UK

"We also see that seladelpar activity is not associated with drug-induced itch, an important benefit for patients with PBC. If these results are maintained over longer periods, we think that seladelpar could offer patients significant advantages over existing treatments," he added.

Giles_55af4ddca6481.jpg


Register here to be notified of future CBAY Company articles
View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.